单位：[1]Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, China.[2]China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.[3]Beijing Key Laboratory of Research of Chinese Medicine on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.[4]China-Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China.[5]China-Japan Friendship hospital, Capital Medical University, Beijing, China.[6]Department of Physiology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, Guangxi, China.[7]Oncology Department of Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.[8]Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, China.[9]Department of Emergency, China-Japan Friendship Hospital, Beijing, China.
Autoimmune diseases (ADs) are closely related to malignant tumours. On the one hand, ADs can increase the incidence of tumours; on the other hand, malignant tumours can cause rheumatic disease-like manifestations. With the increasing depth of analysis into the mechanism of N6-methyladenosine (m6A) modification, it has been found that changes in m6A-related modification enzymes are closely related to the occurrence and development of ADs and malignant tumours. In this review, we explore the pathogenesis of ADs and tumours based on m6A modification. According to systematic assessment of the similarities between ADs and tumours, m6A may represent a common target of both diseases. At present, most of the drugs targeting m6A are in the research and development stage, not in clinical trials. Therefore, advancing the development of drugs targeting m6A is of great significance for both the combined treatment of ADs and malignant tumours and improving the quality of life and prognosis of patients.This article is protected by copyright. All rights reserved.
基金：
National Natural Science Foundation of China
(Grant Numbers U22A20374, 82073677 and
82173378).
第一作者单位：[1]Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, China.[2]China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
通讯作者：
通讯机构：[1]Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, China.[2]China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.[7]Oncology Department of Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.[8]Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, China.[9]Department of Emergency, China-Japan Friendship Hospital, Beijing, China.[*1]Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, China.[*2]Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, China.[*3]Oncology Department of Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
推荐引用方式(GB/T 7714)：
Geng Qishun,Cao Xiaoxue,Fan Danping,et al.Potential medicinal value of m6A in autoimmune diseases and tumours[J].British Journal Of Pharmacology.2023,doi:10.1111/bph.16030.
APA：
Geng Qishun,Cao Xiaoxue,Fan Danping,Wang Qiong,Wang Xing...&Xiao Cheng.(2023).Potential medicinal value of m6A in autoimmune diseases and tumours.British Journal Of Pharmacology,,
MLA：
Geng Qishun,et al."Potential medicinal value of m6A in autoimmune diseases and tumours".British Journal Of Pharmacology .(2023)
医学